智慧药丸市场机会、成长要素、产业趋势分析及2026-2035年预测

全球智慧药丸市场预计到 2025 年价值 13 亿美元，并将以 11.8% 的复合年增长率增长，到 2035 年达到 39 亿美元。

智慧药丸市场的成长主要受胃肠道疾病日益普遍以及对先进诊断技术（旨在减少侵入性检查）需求不断增长的推动。医疗系统正越来越多地采用数位化和基于感测器的医疗解决方案，以提高患者监测和诊断准确性。数据分析、人工智慧和数位健康平台的进步显着增强了口服型医疗设备的功能。人工智慧在处理大量患者数据方面发挥着至关重要的作用，使医疗专业人员能够更有效率地识别健康状况并实施精准的治疗策略。同时，物联网 (IoT) 技术的整合实现了远端监测，使医生无需患者频繁就医即可观察健康指标。这些创新正在改善临床决策，并提高整个诊断流程的效率。随着数位医疗技术的不断发展，智慧药丸正成为现代医疗系统中非侵入性诊断、病患监测和疾病管理日益重要的工具。

智慧药丸是一种口服胶囊，内含电子或机械元件，旨在透过消化道进行诊断、监测或治疗。吞服后，这些胶囊会自然地通过消化器官系统，并在过程中收集重要的生理数据。推动这项技术普及的主要因素之一是人们对微创医疗程序的需求日益增长。与传统诊断技术相比，智慧药丸技术能够提高患者的舒适度，降低併发症风险，并加快康復速度。微电子、无线通讯和感测器工程技术的不断进步也增强了这些设备的性能，使其能够进行即时生理监测，并拓展其潜在的临床应用。

预计到2025年，该产品细分市场的规模将达到8.028亿美元。智慧胶囊配备微型感测器、微处理器和无线通讯技术，可即时传输胃肠道健康、治疗依从性和疾病进展等数据。这些设备提供了一种便捷、非侵入性的方式来监测体内生理状态，同时支持精准的药物传递机制。其易用性和先进的功能使其越来越优于传统的诊断方法。此外，生物相容性材料和先进病患监测技术的日益普及也进一步加速了智慧胶囊的应用。与穿戴式监测设备和数位健康平台的整合也拓展了智慧胶囊在现代医学中的应用范围。

预计到2025年，胃部疾病诊疗市场占有率将达到44%。由于智慧药丸在胃部疾病监测和评估中的应用日益广泛，该领域的重要性日益凸显。专为胃部评估设计的智慧药丸技术能够即时、直观地观察和分析消化系统健康状况。与传统诊断方法相比，这些设备能够更精准地检测和监测胃部疾病，同时最大限度地减少患者的不适感。对胃部疾病精准早期检测需求的不断增长，进一步推动了这项技术的应用。此外，感测器精度、成像能力和无线通讯系统的改进也显着提升了智慧药丸在胃部诊断的应用效果。

预计到2025年，北美智慧药丸市场规模将达到5.035亿美元，并预计在2026年至2035年间以11.5%的复合年增长率成长。该地区的强劲成长得益于先进的医疗基础设施、创新医疗技术的广泛应用以及强大的数位化医疗解决方案。胃肠道疾病和慢性病盛行率的不断上升持续推动着对先进诊断和监测工具的强劲需求。此外，该地区老年人口的成长也促进了支持疾病早期检测和持续监测的医疗技术的广泛应用。成熟的製药和医疗设备製造商的存在也加速了产业创新。对研发、医疗创新计画和政府扶持政策的持续投入，进一步推动了北美智慧药丸市场的稳定扩张。

目录

第一章：调查方法和范围

第二章执行摘要

第三章业界考察

• 生态系分析
• 影响产业的因素
  • 促进因素
    • 胃肠道疾病盛行率增加
    • 智慧药丸技术的持续改进
    • 对非侵入性诊断工具的需求日益增长
  • 产业潜在风险与挑战
    • 严格的监管要求
    • 设备高成本
  • 市场机会
    • 与数位健康生态系统的整合
    • 渗透新兴市场
• 成长潜力分析
• 监理情势（基于初步调查）
  • 北美洲
  • 欧洲
  • 亚太地区
• 科技与创新趋势
  • 目前技术
  • 新兴技术
• 价格分析（基于初步调查）
• 投资和资金筹措趋势
• 人工智慧和生成式人工智慧对市场的影响
• 波特五力分析
• PESTEL 分析

第四章 竞争情势

• 介绍
• 企业市占率分析
• 企业矩阵分析
• 主要市场公司的竞争分析
• 竞争定位矩阵
• 主要进展
  • 併购
  • 伙伴关係与合作
  • 新产品发布
  • 业务拓展计划

第五章 市场估计与预测：依组件划分，2022-2035年

• 产品
  • 胶囊
  • 其他产品
• 病患监测软体

第六章 市场估计与预测：依目标零件划分，2022-2035年

• 胃
• 小肠
• 冒号
• 食道

第七章 市场估计与预测：依应用领域划分，2022-2035年

• 胶囊内视镜
• 标靶药物递送
• 生命征象监测

第八章 市场估算与预测：依最终用途划分，2022-2035年

• 医院
• 诊断中心
• 其他最终用户

第九章 市场估计与预测：依地区划分，2022-2035年

• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国

第十章：公司简介

• ANX Robotica
• Bodycap
• CapsoVision
• Check-Cap
• etectRx
• Intromedic
• Medtronic
• Otsuka Holdings
• Olympus Corporation
• RF Co.

The Global Smart Pills Market was valued at USD 1.3 billion in 2025 and is estimated to grow at a CAGR of 11.8% to reach USD 3.9 billion by 2035.

Growth in the smart pills market is driven by the increasing prevalence of gastrointestinal disorders and the growing demand for advanced diagnostic technologies that reduce the need for invasive procedures. Healthcare systems are increasingly adopting digital and sensor-based medical solutions that improve patient monitoring and diagnostic precision. Technological progress in data analytics, artificial intelligence, and digital health platforms has significantly enhanced the functionality of ingestible medical devices. Artificial intelligence plays an important role in processing large volumes of patient data, allowing healthcare professionals to identify health conditions more efficiently and implement accurate treatment strategies. At the same time, the integration of Internet of Things technologies is enabling remote monitoring capabilities, allowing physicians to observe patient health metrics without requiring frequent hospital visits. These innovations are improving clinical decision-making and enhancing the overall efficiency of diagnostic procedures. As digital healthcare technologies continue to evolve, smart pills are becoming an increasingly important tool for non-invasive diagnosis, patient monitoring, and disease management within modern healthcare systems.

Smart pills are ingestible capsules that contain electronic or mechanical components designed to travel through the gastrointestinal tract for diagnostic, monitoring, or therapeutic purposes. Once swallowed, these capsules move naturally through the digestive system while collecting valuable physiological data. One of the major factors contributing to the adoption of this technology is the growing preference for minimally invasive medical procedures. Compared with traditional diagnostic techniques, smart pill technology offers improved patient comfort, lower risk of complications, and faster recovery. Continuous advancements in microelectronics, wireless connectivity, and sensor engineering have also strengthened the performance of these devices, enabling real-time physiological monitoring and expanding their potential clinical applications.

The product segment generated USD 802.8 million in 2025. Smart capsules are equipped with miniature sensors, microprocessors, and wireless communication technologies that transmit real time data related to gastrointestinal health, treatment adherence, and disease progression. These devices offer a convenient and non-invasive method for monitoring internal physiological conditions while also supporting precise drug delivery mechanisms. Their ease of use and advanced functionality have contributed to their increasing preference over conventional diagnostic approaches. In addition, the growing use of biocompatible materials and advanced patient monitoring technologies has further accelerated the adoption of smart capsules. Integration with wearable monitoring devices and digital health platforms is also expanding their role in modern healthcare.

The stomach segment accounted for 44% share in 2025. This segment holds a significant position due to the increasing application of smart pills in the monitoring and evaluation of stomach related conditions. Smart pill technologies designed for stomach assessment enable real time internal visualization and analysis of digestive health. These devices support accurate detection and monitoring of gastric disorders while minimizing patient discomfort compared with traditional diagnostic procedures. Growing demand for precise and early detection of stomach related diseases has further increased the adoption of this technology. In addition, improvements in sensor accuracy, imaging capabilities, and wireless communication systems have significantly enhanced the effectiveness of smart pill devices used for stomach diagnostics.

North America Smart Pills Market was valued at USD 503.5 million in 2025 and is expected to grow at a CAGR of 11.5% during 2026-2035. The region's strong growth is supported by its advanced healthcare infrastructure, widespread adoption of innovative medical technologies, and strong presence of digital healthcare solutions. Increasing prevalence of gastrointestinal conditions and chronic diseases continues to generate strong demand for advanced diagnostic and monitoring tools. In addition, the growing elderly population within the region is contributing to increased utilization of healthcare technologies that support early disease detection and continuous monitoring. The presence of established pharmaceutical and medical device manufacturers has also accelerated technological innovation within the industry. Continued investments in research, healthcare innovation programs, and supportive government initiatives further contribute to the steady expansion of the smart pills market across North America.

Major companies operating in the Global Smart Pills Market include Medtronic, Olympus Corporation, Otsuka Holdings, CapsoVision, ANX Robotica, Bodycap, Intromedic, Check-Cap, etectRx, and RF Co. Companies operating in the Smart Pills Market are implementing several strategic initiatives to strengthen their market presence and expand technological capabilities. Leading organizations are heavily investing in research and development to enhance sensor technologies, wireless communication systems, and data analytics platforms that improve the performance of ingestible medical devices. Many companies are also focusing on integrating artificial intelligence and connected health technologies to enable advanced diagnostic insights and remote patient monitoring. Strategic collaborations with healthcare providers, research institutions, and digital health companies are helping accelerate product development and clinical adoption. In addition, firms are expanding their global distribution networks and pursuing regulatory approvals in new markets to broaden their geographic reach.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research approach
• 1.3 Quality commitments
  • 1.3.1 GMI AI policy and data integrity commitment
    • 1.3.1.1 Source consistency protocol
• 1.4 Research trail and confidence scoring
  • 1.4.1 Research trail components
  • 1.4.2 Scoring components
• 1.5 Data collection
  • 1.5.1 Partial list of primary sources
• 1.6 Data mining sources
  • 1.6.1 Paid sources
    • 1.6.1.1 Sources, by region
• 1.7 Base estimates and calculations
  • 1.7.1 Revenue share analysis
  • 1.7.2 Base year calculation
• 1.8 Forecast model
• 1.9 Research transparency addendum
  • 1.9.1 Source attribution framework
  • 1.9.2 Quality assurance metrics
  • 1.9.3 Our commitment to trust

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis
  • 2.1.1 Business trends
  • 2.1.2 Regional trends
  • 2.1.3 Component trends
  • 2.1.4 Target area trends
  • 2.1.5 Application trends
  • 2.1.6 End use trends
• 2.2 CXO perspectives: Strategic imperatives

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing prevalence of gastrointestinal disorders
    • 3.2.1.2 Continuous improvements in smart pill technology
    • 3.2.1.3 Growing demand for non-invasive diagnostic tools
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Stringent regulatory requirements
    • 3.2.2.2 High cost of devices
  • 3.2.3 Market opportunities
    • 3.2.3.1 Integration with digital health ecosystems
    • 3.2.3.2 Emerging market penetration
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape (Driven by primary research)
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Technology and innovation landscape
  • 3.5.1 Current technologies
  • 3.5.2 Emerging technologies
• 3.6 Pricing analysis (Driven by primary research)
• 3.7 Investment and funding landscape
• 3.8 Impact of AI and generative AI on the market
• 3.9 Porter's analysis
• 3.10 PESTEL analysis

Chapter 4 Competitive Landscape, 2025

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Key developments
  • 4.6.1 Merger and acquisition
  • 4.6.2 Partnership and collaboration
  • 4.6.3 New product launches
  • 4.6.4 Expansion plans

Chapter 5 Market Estimates and Forecast, By Component, 2022 - 2035 ($ Mn)

• 5.1 Key trends
• 5.2 Product
  • 5.2.1 Capsule
  • 5.2.2 Other products
• 5.3 Patient monitoring software

Chapter 6 Market Estimates and Forecast, By Target Area, 2022 - 2035 ($ Mn)

• 6.1 Key trends
• 6.2 Stomach
• 6.3 Small intestine
• 6.4 Large intestine
• 6.5 Esophagus

Chapter 7 Market Estimates and Forecast, By Application, 2022 - 2035 ($ Mn)

• 7.1 Key trends
• 7.2 Capsule endoscopy
• 7.3 Targeted drug delivery
• 7.4 Vital sign monitoring

Chapter 8 Market Estimates and Forecast, By End Use, 2022 - 2035 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals
• 8.3 Diagnostic centers
• 8.4 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2022 - 2035 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 ANX Robotica
• 10.2 Bodycap
• 10.3 CapsoVision
• 10.4 Check-Cap
• 10.5 etectRx
• 10.6 Intromedic
• 10.7 Medtronic
• 10.8 Otsuka Holdings
• 10.9 Olympus Corporation
• 10.10 RF Co.